Published 1 year ago

Sanofi announces insulin price cap after actions by Ely Lilly and Novo Nordisk

Summary

Sanofi will cap the out-of-pocket cost of its most popular insulin, called Lantus, at $35 per month for people with private insurance, the French drugmaker said Thursday. The change will take effect Jan. 1, 2024.

0 Articles

All

Left

Center

Right

BBC News

Drug giant Sanofi becomes latest to cap US insulin prices

The move follows public outcry over the drug's costs, but it also may help the firms' bottom line.

1 year ago·United Kingdom

Read Full Article

Reuters

Sanofi to cut US price of its most-prescribed insulin by 78%

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .

1 year ago·United Kingdom

Read Full Article

USA Today

3 major insulin makers have now slashed the price of the life-saving drug. Here's why.

Sanofi on Thursday became the last major insulin maker to cut the price of the life-saving drug. Here's why it's been so expensive and what's next.

1 year ago·United States

Read Full Article

CNN

Sanofi becomes latest drugmaker to announce insulin price cuts, capping cost at $35 for the privately insured

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1.

1 year ago·Atlanta, United States

Read Full Article

KIFI

Sanofi becomes latest drugmaker to announce insulin price cuts, capping cost at $35 for the privately insured

By Tami Luhby, CNN Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1. The move follows similar ones by Eli Lilly and Novo Nordisk this month. The three companies dominate the global insulin market. Insulin manufacturers have come under increased public and government…

1 year ago·Idaho Falls, United States

Read Full Article

CNBC

Sanofi Is Latest Drugmaker to Cut Insulin Prices

In addition to its widely prescribed Lantus, the French drugmaker will reduce the list price of its short-acting insulin Apidra by 70%. Sanofi already offers a...

1 year ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.